- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01907113
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single 50 mg Dose of BI 10773 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Type 2 Diabetes and Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase 1 Trial
Visão geral do estudo
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Kiel, Alemanha
- 1245.12.1 Boehringer Ingelheim Investigational Site
-
Neuss, Alemanha
- 1245.12.2 Boehringer Ingelheim Investigational Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
- Male and female subjects with type 2 diabetes
- Renally impaired male or female subjects
- Age 18 - 75 years
- BMI 18 - 34 kg/m2, at least 45 kg for females (Body Mass Index)
- Signed and dated written informed consent
Exclusion criteria:
- Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders as judged by the investigator.
- Relevant gastrointestinal tract surgery
- Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric disorders or relevant neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts; systolic blood pressure < 100 or > 160 mm Hg, diastolic blood pressure < 60 or > 100 mm Hg, pulse rate < 50 or > 100 1/min
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergies) that are deemed relevant to the trial as judged by the investigator
Use within 10 days prior to administration or during the trial of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation. Co medication known to inhibit or induce P-glycoprotein or CYP3A is not allowed. Inhibitors of P-glycoprotein or CYP3A (cytochrom P3A) are e.g.
- protease inhibitors, (e.g. ritonavir, lopinavir nelfinavir)
- azole antimycotics, (itraconazole, ketoconazole, miconazole)
- macrolid antibiotics, (clarithromycin, erythromycin)
- amiodarone, cimetidine, diltiazem, fluvoxamine, mibefradil, nefazodone, verapamil, tacrolimus, quinidine, reserpine, cyclosporine A Inducers of P-gp or CYP3A are e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, ri-fampin, St. John's wort, troglitazone. In dubious cases, a case by case decision will be made after consultation with the sponsor.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: BI 10773 / Group 2
Single Dose Administration (type 2 diabetes and mild renal impairment)
|
oral administration
|
Experimental: BI 10773 / Group 3
Single Dose Administration (type 2 diabetes and moderate renal impairment)
|
oral administration
|
Experimental: BI 10773 / Group 4
Single Dose Administration (severe renal impairment 8)
|
oral administration
|
Experimental: BI 10773 / Group 5
Single Dose Administration (kidney failure)
|
oral administration
|
Experimental: BI 10773 / Group 1
Single Dose Administration (type 2 diabetes and normal renal function)
|
oral administration
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)
Prazo: 1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity.
The areas under the curve were calculated using the linear up/log down algorithm.
If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used.
If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
|
1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Cmax (Maximum Concentration of the Analyte in Plasma)
Prazo: 1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Maximum concentration of Empagliflozin in plasma
|
1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Time to Maximum Concentration of the Analyte in Plasma
Prazo: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Time from last dosing to maximum concentration of Empagliflozin in plasma (tmax)
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Half-life and Mean Residence Time of the Analyte in Plasma
Prazo: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Terminal half-life of Empagliflozin (t1/2) and Mean residence time of Empagliflozin in the body
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Terminal Rate Constant in Plasma
Prazo: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Terminal rate constant in plasma (Lz)
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Apparent Clearance of the Analyte in the Plasma After Extravascular Administration
Prazo: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Apparent clearance of the analyte in the plasma after extravascular administration
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Apparent Volume of Distribution During the Terminal Phase Lz
Prazo: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Apparent volume of distribution during the terminal phase Lz
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
Prazo: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point.
The areas under the curve were calculated using the linear up/log down algorithm.
If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used.
If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)
Prazo: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
Amount of analyte that is eliminated in urine over the time interval 0-96 hours.
|
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)
Prazo: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
Fraction of analyte excreted unchanged in urine from time point 0-96 hours.
|
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
Renal Clearance of the Analyte in Plasma After Extravascular Administration
Prazo: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
Renal Clearance of the Analyte in Plasma After Extravascular Administration for time interval 0-96 hours.
|
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
|
%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)
Prazo: 1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity
|
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
|
Plasma Protein Binding
Prazo: 1 h before drug administration and 1:30 and 3:00 h after drug administration
|
Plasma protein binding is the percent of analyte binding to the plasma protein, pre-dose plasma samples were spiked with Empa 1000 nmol/L. The standard deviation is actually the coefficient of variation. |
1 h before drug administration and 1:30 and 3:00 h after drug administration
|
Total Urinary Glucose Excretion (UGE)
Prazo: 24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration (Interval 24-0 h before drug administration only for baseline UGE)
|
Change from baseline in total urinary glucose excretion
|
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration (Interval 24-0 h before drug administration only for baseline UGE)
|
Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements
Prazo: Drug administration until end-of-study-examination, 5 days
|
Number of participants with clinically relevant findings in physical examination, Vital Signs, Clinically Significant Abnormalities in Electrocardiogram (ECG) and Significant Changes from Baseline Laboratory Measurements
|
Drug administration until end-of-study-examination, 5 days
|
Assessment of Tolerability by Investigator
Prazo: Drug administration until end-of-study-examination, 5 days
|
Tolerability was assessed by the investigator based on adverse events and the laboratory evaluation.
|
Drug administration until end-of-study-examination, 5 days
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1245.12
- 2008-006086-86 (Número EudraCT: EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em BI 10773
-
Boehringer IngelheimEli Lilly and CompanyConcluídoDiabetes Mellitus, Tipo 2Estados Unidos, Argentina, Austrália, Áustria, Bélgica, Brasil, Canadá, Colômbia, Croácia, República Checa, Dinamarca, Estônia, França, Geórgia, Grécia, Hong Kong, Hungria, Índia, Indonésia, Israel, Itália, Japão, Republica da Coréia, M... e mais
-
Boehringer IngelheimConcluídoDiabetes Mellitus, Tipo 2Alemanha
-
Boehringer IngelheimEli Lilly and CompanyConcluídoDiabetes Mellitus, Tipo 2Estados Unidos, Argentina, Austrália, Canadá, El Salvador, Alemanha, Itália, Portugal, Federação Russa, Espanha, Ucrânia
-
Boehringer IngelheimEli Lilly and CompanyConcluídoDiabetes Mellitus, Tipo 2Estados Unidos, Dinamarca, França, Irlanda, Republica da Coréia, Portugal, Reino Unido
-
Boehringer IngelheimEli Lilly and CompanyConcluídoDiabetes Mellitus, Tipo 2Estados Unidos, Canadá, China, França, Alemanha, Índia, Republica da Coréia, México, Eslováquia, Eslovênia, Taiwan, Peru
-
Boehringer IngelheimConcluído
-
Boehringer IngelheimConcluído
-
Boehringer IngelheimConcluídoDiabetes Mellitus, Tipo 2Alemanha
-
Boehringer IngelheimEli Lilly and CompanyConcluídoDiabetes Mellitus, Tipo 2Estados Unidos, Argentina, Austrália, Brasil, Bulgária, Canadá, Colômbia, Dinamarca, Estônia, Hungria, Itália, Líbano, Malásia, México, Peru, Filipinas, Polônia, Romênia, Federação Russa, Espanha, Suécia, Taiwan
-
Boehringer IngelheimConcluído